NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $0 | – | 250 | 0.0% | 0.00% | – |
Q2 2023 | $0 | – | 250 | 0.0% | 0.00% | – |
Q1 2023 | $0 | -100.0% | 250 | -70.2% | 0.00% | – |
Q4 2022 | $2 | -100.0% | 839 | -83.8% | 0.00% | – |
Q3 2022 | $17,000 | +1600.0% | 5,179 | +3521.7% | 0.00% | – |
Q2 2022 | $1,000 | -92.9% | 143 | -94.5% | 0.00% | – |
Q1 2022 | $14,000 | +366.7% | 2,619 | +923.0% | 0.00% | – |
Q4 2021 | $3,000 | +50.0% | 256 | +156.0% | 0.00% | – |
Q2 2021 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q1 2021 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q4 2020 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q3 2020 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q2 2020 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q1 2020 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q4 2019 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q3 2019 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q2 2019 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q1 2019 | $2,000 | +100.0% | 100 | +163.2% | 0.00% | – |
Q4 2018 | $1,000 | – | 38 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |